Gastrointestinal Stromal Tumours (GISTs) with KRAS Mutation: A Rare but Important Subset of GISTs

1 Division of Anatomical Pathology, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada
2 Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada
3 Department of Cellular Pathology, Southmead Hospital, Bristol, UK
4 Deciphex, Dublin, Ireland

Correspondence should be addressed to Runjan Chetty; runjan.chetty@gmail.com

Received 25 May 2022; Revised 27 September 2022; Accepted 10 July 2023; Published 24 August 2023

Academic Editor: Yoshifumi Nakayama

Copyright © 2023 Dorinda Mullen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the GI tract, usually found in the stomach, jejunum, and ileum. Typically, they are KIT or PDGFR-mutated, allowing for targetable treatments with tyrosine kinase inhibitors such as imatinib. Here, we present two KRAS-mutated wild-type gastrointestinal tumours (GISTs). Both cases occurred in the small bowel of females. Immunohistochemical studies on both tumours showed KIT and DOG-1 positivity, with SDHB retained. Molecular analysis revealed a KRAS G12D mutation and a KRAS G13D mutation, respectively. Wild-type GISTs are extremely uncommon. They typically occur in the stomach or the small bowel. KRAS is one of the genes implicated in this subset of GIST, with KRAS G12D being the most frequently encountered mutation. GIST KRAS mutations can arise alone or in conjunction with KIT, PDGFRA, or BRAF mutations. Identification of these rare molecular subtypes is clinically important due to their resistance to imatinib therapy.

1. Introduction

Gastrointestinal stromal tumours (GISTs) are an established tumour group with the vast majority possessing characteristic morphology, immunohistochemical profiles, molecular findings, and specific targeted therapeutic agents. A small subset of GISTs fall outside of the usual molecular paradigm of KIT or platelet-derived growth factor alpha (PDGFRA) or succinate dehydrogenase (SDH) mutations which account for 85% of cases. Tumours lacking these mutations are regarded as wild-type GIST. Of the remaining 15% of GISTs, most will harbour neurofibromatosis-1 (NF-1) or second RAF paralogue (BRAF) mutations. The least frequently encountered are those bearing a Kirsten rat sarcoma (KRAS) mutation. Although this molecular scenario is extremely uncommon, its awareness is important because of the therapeutic ramifications for patients.

We present two sporadic GIST cases highlighting the practical issues associated with wild-type GIST, review the pertinent literature on this unusual GIST molecular scenario, and provide a comprehensive summary of the immunohistochemical-molecular associations in GIST.

2. Materials and Methods

Specimens were received in 10% neutral buffered formalin, and 10 sections were taken from the tumour. These were processed in a routine manner generating haematoxylin and eosin-stained sections.
Immunohistochemistry was performed on the formalin fixed, paraffin embedded tissue for KIT (CD117), DOG-1, CD34, desmin, caldesmon, smooth muscle actin, S100, cytokeratin AE1/3, and succinate dehydrogenase (SDHB). Appropriate positive and negative controls were run in parallel.

2.1. Molecular Analysis for Case 1. Mutational analysis by next generation sequencing (NGS) was performed using the TruSight-15 panel (Illumina) that targets entire coding regions or hotspot sequences of 15 genes including the following: KIT, PDGFRA, BRAF, NRAS, KRAS, PIK3CA, AKTI, EGFR, ErbB2, RET, and p53. The NGS panel was run on two different sampled areas of the tumour.

Specific to KIT and PDGFRA, the NGS panel covered the following exons:
- KIT: exons 8–11, 13-14, and 17-18 and PDGFRA: exons 12, 14, and 18.

2.2. Molecular Analysis for Case 2. Sanger sequencing was performed on KIT exons 9, 11, 13, and 17 and PDGFRA exons 12, 14, and 18; pyrosequencing was performed on BRAF exons 11 and 15; real time amplification refractory mutation system polymerase chain reaction (ARMS PCR) was performed for PIK3CA exons 9 and 20 and pyrosequencing was performed covering KRAS and NRAS codons 12, 13, 59, 61, 117, and 146.

3. Case Summary

3.1. Case 1. A 77-year-old female with a history of squamous cell carcinoma of the perianal region that was treated with chemoradiation was noted to have a 6 cm solid-cystic mass in the right pelvic region on surveillance MRI. She did not have any other relevant clinical history, and there was no family history of malignancies or neurofibromatosis type 1.

The mass arose from the ileum and was densely adherent to the uterus. Histological sections demonstrated a well-circumscribed neoplasm arising from the muscularis propria composed of spindle cells with eosinophilic cytoplasm arranged in fascicles. There was moderate nuclear pleomorphism with scattered multinucleated and giant cells. Oedema, microplysm and cystic degeneration were also noted (Figure 1). The mitotic rate was 2 per 5 mm². There was no necrosis, infarction, or lymphovascular invasion. Immunohistochemistry showed strong and diffuse positivity for CD117, DOG-1, and CD34 and negative for S100, SMA, desmin, and pan-keratin. There was retention of staining with SDHB immunohistochemistry. Molecular studies identified a KRAS p.Gly13Asp (commonly known as G13D) activating mutation.

A final diagnosis was of a KRAS G13D-mutated, high risk, mixed-cell type GIST of small bowel origin. Unfortunately, no follow-up information is available on this patient.

Thus, both these GISTs were wild-type (intact KIT, PDGFRA, and SDH genes or SDH-competent) GISTs with a KRAS mutation.

4. Discussion

85–90% of GISTs will harbour a mutation in either one of the receptor tyrosine kinase genes KIT or PDGFRA. In routine practice, most mutational analyses are geared towards seeking activating mutations in these two genes. In approximately 15% of GISTs, both KIT and PDGFRA genes are found to be intact and so is referred to as a KIT/ PDGFRA wild-type GIST. This molecular profile is most frequently encountered in paediatric GISTs, and when seen in adult patients, it is sometimes referred to as paediatric-like GIST [1–4]. In wild-type GISTs, the vast majority (85%), will have a mutation or epimutation in the SDH complex of genes. These GISTs are characterised by SDH protein deficiency and are also referred to as SDH-deficient GISTs. In the remaining 20% of wild-type GISTs, the SDH gene complex is also normal or wild type, resulting in the so-called KIT/PDGFRA/SDH wild-type or SDH-competent GIST. The next most frequent genes involved in KIT/PDGFRA/SDH-wild-type GIST are NF-1 and BRAF [5, 6]. Although NF-1 mutations were not sought in either of the cases presented herein, there was no family history or clinical stigmata to suggest that they were neurofibromatosis patients.

There are approximately 1% of GISTs that are wild type for KIT, PDGFRA, SDH, NF-1, and BRAF. A plethora of genes have been implicated in this particular subset of GISTs such as PIK3CA, NRAS, HRAS, and KRAS. Rare examples described in the literature include alterations and point mutations in the fibroblast growth factor/receptor (FGF/FGFR) signalling pathway and gene fusions such as ETV6-NTRK, FGFR1-TACC1, and CDC42BPBALK [7–11].

Following next generation sequencing analysis, our two cases fall into this last category of GIST and are characterised by KRAS mutations. KRAS-mutated GISTs share morphological and immunohistochemical properties with KIT/PDGFRA-mutated GISTs. In addition to the spindle
and/or epithelioid cell morphology, these GISTs are also KIT and DOG-1 positive by immunohistochemistry (Table 1). Thus, if mutational analysis is restricted only to activating mutations in KIT, PDGFRA, SDHB, and BRAF, this rare subgroup of GISTs would not be detected. Furthermore, it is also known that KRAS-mutated GISTs are resistant to first line receptor tyrosine kinase inhibitors and so are clinically relevant.

As a group, KRAS-mutated GISTs are exceedingly rare and thought to account for 0.2% of all GISTs, although a detailed molecular analysis of 514 cases failed to detect any cases with KRAS mutations [12].

Table 2 highlights the pertinent literature and findings of KRAS-mutated GISTs. In 2012, Miranda et al. [13] highlighted 3 cases of GIST with KRAS and coexistent KIT (2 cases) and PDGFRA (1 case). One of the cases contained two separate KRAS mutations. Two cases were in the stomach, and a case with KRAS and PDGFRA mutations was in the small bowel. The KRAS mutations occurred at the following residue positions: G12D, G13D, G12A, and G12D. No details on demographics, histological features, and immunohistochemistry were provided.

Antonescu et al. [14] also encountered a GIST with concomitant KRAS and KIT mutations in the small bowel of a 66-year-old male. The tumour was described as anaplastic with rhabdoid cells and was negative for KIT by immunohistochemistry although the pretreated GIST was not stained. The patient also received preoperative imatinib. The KRAS mutation occurred at residue G12V.

Serrano et al. [15] also encountered a KRAS- and KIT-mutated GIST in the stomach of a 61-year-old male. The GIST had spindle cell morphology and was KIT positive by immunohistochemistry, and the KRAS mutation was at residue G12R.

The case described by Hechtman et al. [16] was a KRAS-only mutated GIST. It arose in the stomach of a 67-year-old man, was positive for KIT immunohistochemistry, and had lost SDHB protein expression. There is limited information on the one case described by Gao et al. [17] with a KRAS only mutation except that the mutation occurred at residue G13D. They also encountered other KRAS mutations in combination with BRAF mutations [17].

A KRAS-only mutated GIST was described by Mavroeidis et al. [18] describes in a male patient with a G12D
Table 1: Immunohistochemical molecular scenarios in gastrointestinal stromal tumours (GISTs).

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>% of GIST</th>
<th>Immunohistochemistry</th>
<th>Molecular</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>KIT</td>
<td>DOG1</td>
</tr>
<tr>
<td>(i) Usual GIST</td>
<td>85–90%</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>(ii) KIT/PDGFRα SDH-deficient GIST</td>
<td>10–15%</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>(iii) KIT/PDGFRα/SDH GIST</td>
<td>1-2%</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>(iv) KIT/PDGFRα/SDH GIST</td>
<td>&lt;1%</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>(v)</td>
<td>&lt;1%</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>(vi)</td>
<td>Rare</td>
<td>Neg</td>
<td>Pos</td>
</tr>
<tr>
<td>(vii) ***</td>
<td>Very rare</td>
<td>Neg</td>
<td>Neg</td>
</tr>
</tbody>
</table>

Pos = positive; Neg = negative; Wt = wild type; * = KIT or PDGFRα is mutated; ** = BRAF or NF1 is mutated; *** = this is a very rare scenario, and all tests should be repeated. Consideration whether this is in fact a GIST should be entertained.
KRAS mutation in his gastric GIST. The patient had a subtotal gastrectomy, was treated with imatinib but relapsed quickly, and died within 15 months of diagnosis.

Thus, KRAS mutations in GIST occur in two distinct scenarios as follows:

(i) KRAS mutations coexisting with other mutations such as KIT, PDGFRA, and BRAF. This appears to be the commoner scenario in which KRAS mutations occur in GISTs.

(ii) KRAS mutations only/exclusively.

The KRAS gene is one of the most frequently mutated genes in human cancers. Within the gene, activating mutations are most often seen at residue positions 12, 13, and 61, with the G12 residue being mutated 80% of the time [19]. Of these, G12 mutates to aspartate (G12D) in 36% of cases, to valine (G12V) in 23%, and cysteine (G12C) in 14% [19].

KRAS is located downstream to both KIT and PDGFRA, and there is no obvious explanation as to why both KIT and DOG1 immunohistochemistry are positive in a GIST harbouring a KRAS mutation. Since only specific exons in the KIT and PDGFRA genes were examined by NGS, it remains possible that other untested exons of the genes may have been mutated resulting in protein overexpression. In the absence of this, a possible feedback loop between the RAS signal transduction pathway and KIT may result in KIT protein overexpression.

### 5. Conclusion

This overview highlights a rare cohort of wild-type GISTs that bear KRAS mutations. While being distinctly rare, they are important to recognise from a therapeutic and prognostic point of view as the KRAS mutation confers resistance to imatinib therapy. Furthermore, our case report raises the issue as to whether all GISTs should have reflex molecular testing rather than relying on immunohistochemistry only.

In these two particular cases, based on the immunohistochemical results (Table 1) solely, it may have been assumed that the GISTs contain a KIT or PDGFRA mutations. If this did indeed occur, the patient would have been treated, unsuccessfully, with imatinib. Performing a full molecular analysis to detect a rare (1% of cases) subset of GISTs has to be balanced with the cost associated with this approach.

### Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### References


